Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19

Phase 3 Suspended 6400 enrolled University of Birmingham Christian Medical College and Hospital, Ludhiana, India · collab Hospital Español Veracruz · collab Istituto Clinico Humanitas · collab Kigali University Teaching Hospital · collab Ministry of Health, Ghana · collab University of Cape Town · collab University of Edinburgh · collab University of Lagos, Nigeria · collab University of Witwatersrand, South Africa · collab Université d'Abomey-Calavi · collab

RandomizedParallel-groupOpen-labelPrevention

Summary

The aim of this study is to reduce pulmonary complications in adult patients undergoing abdominal or thoracic surgery in COVID-19 exposed hospital environments. A Trial in Low and Middle Income Countries (LMICs)

Timeline

Start: 2022-05-16
Primary completion: 2026-12-31
Completion: 2027-03-01

Outcome

Outcome not reported

Stopped: “Lack of IMP availability - may resume.”

Publications

Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mannitol	Diagnostic / imaging agent	—	Inhaled
Subject	Sodium Nitrite	Small molecule	—	Inhaled
Subject	citric acid	Unknown	—	Inhaled